Quick Answer
Sunshine Biopharma Inc. reported Gross Profit of $10.67 million for the year ending 2024.
- Sunshine Biopharma Inc. showed an increase of +27.9% in Gross Profit from 2023 to 2024.
- This data is from Sunshine Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $0.00 | Q3 2017: $0.00 | Q1 2018: -$9.7 thousand | Q2 2018: $0.00 | Q3 2018: $0.00 | Q1 2019: $94.00 | Q2 2019: $1.6 thousand | Q3 2019: $2.0 thousand | Q1 2020: $7.2 thousand | Q2 2020: $10.0 thousand | Q3 2020: $10.8 thousand | Q1 2021: $21.5 thousand | Q2 2021: $34.4 thousand | Q3 2021: $30.9 thousand | Q1 2022: $62.8 thousand | Q2 2022: $75.6 thousand | Q3 2022: $67.0 thousand | Q1 2023: $1.83 million | Q2 2023: $1.95 million | Q3 2023: $1.99 million | Q1 2024: $2.35 million | Q2 2024: $2.36 million | Q3 2024: $2.87 million | Q1 2025: $2.73 million | Q2 2025: $3.42 million | Q3 2025: $3.07 million.
- Historical annual values: Fiscal year 2024: $10.67 million | Fiscal year 2023: $8.34 million | Fiscal year 2022: $1.70 million | Fiscal year 2021: $110.6 thousand | Fiscal year 2020: $45.6 thousand | Fiscal year 2019: $10.1 thousand | Fiscal year 2018: $0.00 | Fiscal year 2017: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: